What Priavoid does

Priavoid GmbH is a privately held, clinical-stage biopharmaceutical company founded in September 2017 in Düsseldorf, Germany, as a spin-off from Forschungszentrum Jülich and Heinrich Heine University Düsseldorf. The company develops orally available all-D-peptide therapeutics designed to selectively bind and disassemble neurotoxic oligomeric protein aggregates — the proposed root cause of several neurodegenerative diseases. Its core platform uses mirror-image phage display selection combined with rational design to generate D-enantiomeric peptides that cross the blood-brain barrier, enter target cells, are non-immunogenic, and disassemble toxic oligomers into harmless monomers. The pipeline is led by PRI-002 in Phase 2 clinical development for Alzheimer's disease (PRImus-AD trial, fully recruited February 2025 with 304 patients across 40 centers in 6 European countries), followed by PRI-101 (preclinical, targeting alpha-synuclein in Parkinson's disease and synucleinopathies, funded by the Michael J. Fox Foundation), PRI-200 (preclinical tau program, funded under the Alzheimer's Association/Rainwater T-PEP), and an ALS discovery effort.

The company operates with 11–50 employees at the Life Science Center Düsseldorf under a leadership team anchored by CEO Philipp Bürling, CSO and co-founder Prof. Dr. Dieter Willbold, and CMO Prof. Dr. Oliver Peters (joined July 2025), with Nobel laureate Prof. Dr. Stanley Prusiner on the supervisory board. Priavoid has no commercial products and no reported revenue; its business model is a classic clinical-stage licensing/royalty model in which successful Phase 2/3 data is intended to unlock out-licensing deals, co-development agreements, and eventual royalty streams with larger pharmaceutical partners for late-stage development and commercialization. Capitalization combines a EUR 7 million Series A (February 2021, led by Riesner Verwaltungs GmbH and HBG) with significant non-dilutive funding from SPRIND/BMBF (via PRInnovation GmbH as PRImus-AD sponsor), the Michael J. Fox Foundation, the Alzheimer's Association, and the Rainwater Charitable Foundation. GTM activity is concentrated on enterprise partnering through scientific conferences (BIO International, Swiss Biotech Day, AD/PD) and direct outreach to pharmaceutical partners.

Name

Priavoid

Legal name

Priavoid GmbH

Website

https://priavoid.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Priavoid GmbH is a privately held, clinical-stage biopharmaceutical company developing orally available all-D-peptide therapeutics that disassemble neurotoxic protein aggregates to treat Alzheimer's, Parkinson's, tauopathies, and ALS, pursuing an out-licensing model with pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceutical Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)

Keywords

• Clinical-stage biopharmaceuticals
• All-D-peptide therapeutics
• Neurodegenerative disease treatments
• Anti-prionic drug discovery
• Protein aggregation inhibitors

Headquarters

HQ city

Düsseldorf

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Licensing/Royalty Revenue: As a clinical-stage biopharmaceutical company developing disease-modifying therapeutics, Priavoid's revenue model centers on licensing its technology and drug candidates to larger pharmaceutical partners. The company is pursuing a land-and-expand strategy where successful Phase 2/3 data would enable partnership deals including upfront payments, milestone payments, and royalty streams on commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Priavoid GmbH develops a clinical-stage pipeline of orally available all-D-peptide drug candidates designed to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. The lead asset PRI-002 targets toxic amyloid-beta oligomers for Alzheimer's disease (Phase 2 PRImus-AD trial), with PRI-101 in preclinical development for synucleinopathies (Parkinson's, MSA) and PRI-200 in preclinical development for tauopathies, all powered by a proprietary mirror-image phage display detangler platform.

Product overview

Priavoid is developing a novel class of orally available all-D-peptide therapeutics targeting neurodegenerative diseases. The company’s pipeline consists of lead program PRI-002 (Phase 2, Alzheimer’s disease targeting amyloid-beta oligomers), PRI-101 (preclinical, Parkinson’s disease targeting alpha-synuclein), and PRI-200 (preclinical, tauopathies targeting tau aggregates), supported by a proprietary all-D-peptide detangler platform. All candidates use the same core detangler mechanism to disassemble toxic oligomers into harmless monomers, with additional discovery programs targeting other neurodegenerative disorders like ALS.

Differentiator

Problem solved

Functional benefit

Products and services

• PRI-002 Lead clinical drug candidate; an orally available all-D-peptide that selectively binds and disassembles toxic amyloid-beta (Aβ) oligomers into harmless monomers for the treatment of Alzheimer's disease. Currently in Phase 2 (PRImus-AD), fully recruited with 304 patients across 40 centers in 6 European countries.
• PRI-101 Preclinical all-D-peptide drug candidate designed to detangle pathological α-synuclein aggregates for the treatment of synucleinopathies including Parkinson's disease and multiple system atrophy (MSA). Demonstrated α-synuclein aggregate disassembly in vitro, ex vivo in PD/MSA/Lewy body dementia patient brains, and in vivo in PD mouse models.
• PRI-200 Preclinical all-D-peptide drug candidate targeting tau aggregates for the treatment of tauopathies including Alzheimer's disease, Pick's disease, frontotemporal dementia, and Progressive Supranuclear Palsy. Designed to bind specific subunits within tau aggregates and force them toward a native, non-toxic conformation.
• All-D-Peptide Detangler Platform Proprietary drug discovery and development platform employing mirror-image phage display selection technology combined with rational design optimization to generate orally available, non-immunogenic, blood-brain-barrier-penetrant all-D-peptide therapeutics that selectively bind and disassemble neurotoxic protein aggregates. Applicable across multiple neurodegenerative indications including Alzheimer's, Parkinson's, tauopathies, and ALS.

Quantifiable outcome

• ARIA-E rate of 2.2% and ARIA-H rate of 6.7% in blinded PRImus-AD population, consistent with placebo rates in Phase 3 antibody trials
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• PRInnovation GmbH (SPRIND)coreStrategic or Co-development Partner · 4 February 2021PRInnovation GmbH, a subsidiary of Federal Agency for Disruptive Innovation (SPRIND), entered into a research collaboration in 2021 to advance the clinical development of Priavoid's Alzheimer's program PRI-002. PRInnovation serves as the sponsor for the PRImus-AD Phase 2 clinical trial, which is funded by SPRIND with funds from the German Federal Ministry of Education and Research (BMBF).
• Stanley Prusiner (Supervisory Board)coreOthers · 9 December 2020Nobel Prize winner (1997) in Physiology or Medicine for discovery of prions. Joined Priavoid's supervisory board in December 2020. Director of the Institute for Neurodegenerative Diseases at UCSF. Provides scientific expertise and credibility to the anti-prionic treatment approach.
• Forschungszentrum Jülich (FZJ)coreStrategic or Co-development PartnerForschungszentrum Jülich is the scientific origin of Priavoid's platform technology, developed by Prof. Dr. Dieter Willbold at the Institute of Structural Biochemistry (IBI-7). Close scientific collaboration continues, including the Michael J. Fox Foundation-funded project on alpha-synuclein with Prof. Dr. Erdem Tamgüney.
• Heinrich-Heine-University Düsseldorf (HHU)coreStrategic or Co-development PartnerHeinrich-Heine-University Düsseldorf is where Prof. Dr. Dieter Willbold serves as Professor for Physical Biology. The Institute of Physical Biology led by Prof. Willbold is the academic origin of Priavoid's technology platform. Close scientific exchange and collaboration continue.

Scale indicators4 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• AC Immune SA: Swiss clinical-stage biotech with a pipeline of vaccines, antibodies, and small molecules targeting amyloid-beta, tau, and alpha-synuclein in Alzheimer's and Parkinson's. Comparable in clinical-stage status, neurodegenerative protein-aggregation focus, and European base.
• BioArctic AB: Swedish clinical-stage biotech with lecanemab (now approved as Leqembi via Eisai partnership) for Alzheimer's and antibody programs targeting alpha-synuclein for Parkinson's. Comparable as a European neurodegenerative biotech developing protein-aggregation-targeted therapeutics.
• Anavex Life Sciences: Clinical-stage biotech developing small-molecule therapies (blarcamesine/ANAVEX2-73) targeting sigma-1 receptors for Alzheimer's, Parkinson's, and Rett syndrome. Comparable as a clinical-stage neurodegeneration company pursuing disease-modifying therapies.
• Prothena Corporation: Clinical-stage biotech developing antibody-based therapeutics targeting amyloid-beta, tau, and alpha-synuclein for Alzheimer's, Parkinson's, and other neurodegenerative diseases. Directly comparable as a protein-aggregation-focused neurodegeneration company with multiple clinical-stage programs.
• Athira Pharma: Clinical-stage biotech developing small-molecule therapies (fosgonimeton) targeting HGF/MET for Alzheimer's and Parkinson's. Comparable as a clinical-stage company focused on disease-modifying neurodegenerative therapies.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegeneration including programs targeting amyloid-beta, LRRK2, and other CNS pathways. Comparable as a clinical-stage biotech with multi-program neurodegenerative pipeline and platform approach.
• Cassava Sciences: Clinical-stage biotech developing simufilam, an oral small-molecule therapy for Alzheimer's disease. Comparable in clinical-stage focus on Alzheimer's, oral administration profile, and disease-modifying therapeutic positioning.

Broad incumbents

• Biogen: Large commercial-stage biopharma with multiple approved and clinical-stage neurodegenerative therapies including Leqembi (lecanemab, co-developed with Eisai) for Alzheimer's. Comparable as the most directly relevant large incumbent in neurodegenerative therapeutics and a likely Priavoid partnership counterparty.
• Eli Lilly: Large commercial-stage pharma with Kisunla (donanemab) approved for Alzheimer's, extensive neurodegeneration pipeline including tau and Parkinson's programs. Comparable as a likely Priavoid partnership counterparty given its dominant position in the AD therapeutic space.
• Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for CNS diseases including Alzheimer's and Parkinson's. Comparable as a clinical-stage CNS biotech targeting neurodegenerative diseases, though Priavoid's all-D-peptide modality is distinct from gene therapy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/priavoid-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Priavoid